Citations

Showing 10 of 108152 citations.

Delineating the physiology of cryoballoon ablation
Su, Wilber , Tomaiko, Emrie, Tseng, Andrew , Su, Wilber W , Tseng, Andrew S.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | August 5, 2019 | Volume: 30 | Issue: 10 | Pages: 2088-2089

10.1111/jce.14096 | PMID 31379039 Get It

New Tools for Finding Full-Text Articles Faster: Kopernio, Nomad, Unpaywall, and More
Hoy, Matthew B.

Mayo Clinic

Medical Reference Services Quarterly | August 5, 2019 | Volume: 38 | Issue: 3 | Pages: 287-292

10.1080/02763869.2019.1629215 | PMID 31379291 Get It

Intracranial cellular schwannomas: a clinicopathological study of 20 cases
Costa, Felipe D’Almeida , Dias, Tiago Miranda , Lombardo, Kara A. , Kenyon, Lawrence C. , Saad, Ali G., Gökden, Murat , Burger, Peter C. , Raghunathan, Aditya , Giannini, Caterina , Montgomery, Elizabeth Anne , Rodríguez, Fausto J.

Mayo Clinic

Histopathology | August 5, 2019 | Volume: 76 | Issue: 2 | Pages: 275-282

10.1111/his.13967 | PMID 31379028 Get It

AimsCellular schwannoma is a specific subtype of schwannoma, prone to misinterpretation as a malignant neoplasm. Involvement of the intracranial compartment by these tumours is extremely rare. We aim to characterise this clinicopathological subgroup.Methods and resultsWe identified a total of 20 cellular schwannomas with predominant intracranial involvement. The mean age of the patients at the time of surgery was 37 years (range = 16–81), with a slight female predominance (1.5:1 ratio). The most common sites were the eighth (n = 8) and fifth (n = 6) cranial nerves. Three tumours involved the anterior cranial fossa/olfactory groove, and a single case involved the glossopharyngeal nerve. All tumours met established criteria for cellular schwannoma, and were composed of interlacing fascicles of spindle cells lacking Verocay bodies with minimal Antoni B pattern and variable chronic inflammation and foamy histiocytes. Rare findings included haemosiderin deposition (n = 6), necrosis (n = 4), brisk mitotic activity (>10 mitoses per 10 high‐power fields) (n = 2), focal epithelioid morphology (n = 2), myxoid areas (n = 2), neuroblastoma‐like pattern (n = 1) and granular cells (n = 1). Immunohistochemical stains demonstrated expression of Schwann cell markers (S100 protein, SOX10, collagen IV) and preserved H3 K27 trimethylation in all cases tested. Fourteen patients had postoperative follow‐up, ranging from 2 months to 21 years (mean = 66 months). In patients with follow‐up, local recurrence/persistence developed in six cases; five tumours were initially incompletely resected. No metastatic disease or deaths were reported.ConclusionsIntracranial cellular schwannomas share morphological and immunophenotypical features with cellular schwannomas at others sites may demonstrate locally aggressive growth but appear to lack metastatic potential.
Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer‐associated venous thromboembolism
Wysokiński, Waldemar E. , Houghton, Damon E. , Casanegra, Ana I. , Vlazny, Danielle T. , Bott‐Kitslaar, Dalene , Froehling, David A. , Hodge, David O. , Peterson, Lisa , Bott-Kitslaar, Dalene M, Peterson, Lisa G, McBane, Robert D. , Wysokinski, Waldemar , Houghton, Damon E , Casanegra, Ana I

Mayo Clinic

American Journal of Hematology | August 5, 2019 | Volume: 94 | Issue: 11 | Pages: 1185-1192

10.1002/ajh.25604 | PMID 31378995 Get It

Abstract To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer‐associated venous thromboembolism (Ca‐VTE), consecutive patients treated with apixaban, rivaroxaban, or enoxaparin at Mayo Thrombophilia Clinic (March 1, 2013 to January 31, 2018)) were followed prospectively. The primary effectiveness outcome was venous thromboembolism (VTE) recurrence, and the secondary was mortality. The primary safety outcome was major bleeding, the secondary clinically relevant safety outcome was non‐major bleeding (CRNMB), and the third a composite of major and CRNMB. There were 750 patients treated for acute Ca‐VTE with apixaban (n = 224), rivaroxaban (n = 163), and enoxaparin (n = 363) within 14 days of diagnosis and for at least 3 months, or until study event. Recurrent VTE was diagnosed in 11 receiving apixaban, 7 receiving rivaroxaban (apixaban vs rivaroxaban hazard ratio (HR) 1.31, 95% confidence interval (95% CI) 0.51‐3.36) and 17 in the enoxaparin receiving group (apixaban vs enoxaparin HR 1.14, 95% CI: 0.54, 2.42 and rivaroxaban vs enoxaparin HR 0.85, 95% Cl: 0.36, 2.06). There were 82 deaths in apixaban, 74 rivaroxaban (apixaban vs rivaroxaban HR 1.67, 95% Cl: 1.20, 2.33) and 171 in enoxaparin group (rivaroxaban vs enoxaparin HR 0.73, 95% Cl: 0.56, 0.96). Major bleeding occurred in 11 apixaban, 12 rivaroxaban (apixaban vs rivaroxaban HR 0.73, 95% Cl: 0.32, 1.66) and 21 enoxaparin group (apixaban vs enoxaparin HR 0.89, 95% Cl: 0.43, 1.84 and rivaroxaban vs enoxaparin HR 1.23, 95% Cl: 0.61, 2.50). The CRNMB rate was higher in rivaroxaban compared to apixaban ( P = .03) and LMWH ( P = .01) groups. Recurrence of VTE and major bleeding were similar in apixaban, rivaroxaban, and enoxaparin groups. Rivaroxaban was associated with higher CRNMB but lower mortality compared to apixaban and enoxaparin.
Re: Ileocolic intussusception from an inflammatory fibroid polyp: a rare cause of adult small bowel obstruction
Rajesh, Aashish , Chandra, Abhishek

Mayo Clinic

ANZ Journal of Surgery | August 5, 2019 | Volume: 89 | Issue: 7-8 | Pages: 981-982

10.1111/ans.15294 | PMID 31379078 Get It

Palliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statement
Sobański, Piotr , Alt‐Epping, Bernd , Currow, David C. , Goodlin, Sarah J. , Hogg, Karen , Janssen, Daisy J.A. , Johnson, Miriam J. , Krajnik, Małgorzata , Leget, Carlo , Moroni, Matteo , Mueller, Paul S. , Ryder, Mary , Stowe, Emily , Grodzicki, Tomasz K. , Martínez-Sellés, Manuel , Simon, Steffen T. , Larkin, Philip Joseph

Mayo Clinic

Cardiovascular Research | August 3, 2019 | Volume: 116 | Issue: 1 | Pages: 12-27

10.1093/cvr/cvz200 | PMID 31386104 Get It

AbstractContrary to common perception, modern palliative care (PC) is applicable to all people with an incurable disease, not only cancer. PC is appropriate at every stage of disease progression, when PC needs emerge. These needs can be of physical, emotional, social, or spiritual nature. This document encourages the use of validated assessment tools to recognize such needs and ascertain efficacy of management. PC interventions should be provided alongside cardiologic management. Treating breathlessness is more effective, when cardiologic management is supported by PC interventions. Treating other symptoms like pain or depression requires predominantly PC interventions. Advance Care Planning aims to ensure that the future treatment and care the person receives is concordant with their personal values and goals, even after losing decision-making capacity. It should include also disease specific aspects, such as modification of implantable device activity at the end of life. The Whole Person Care concept describes the inseparability of the physical, emotional, and spiritual dimensions of the human being. Addressing psychological and spiritual needs, together with medical treatment, maintains personal integrity and promotes emotional healing. Most PC concerns can be addressed by the usual care team, supported by a PC specialist if needed. During dying, the persons’ needs may change dynamically and intensive PC is often required. Following the death of a person, bereavement services benefit loved ones. The authors conclude that the inclusion of PC within the regular clinical framework for people with heart failure results in a substantial improvement in quality of life as well as comfort and dignity whilst dying.
A four‐gene transcript score to predict metastatic‐lethal progression in men treated for localized prostate cancer: Development and validation studies
Cheng, Anqi , Zhao, Shanshan , Wright, Jonathan L. , Kolb, Suzanne , Karnes, R. Jeffrey , Jenkins, Robert B. , Ostrander, Elaine A. , Feng, Ziding , Fan, Jian‐Bing , Dai, James Y. , Stanford, Janet L. , Stanford, Janet L , Dai, James Y , FitzGerald, Liesel M. , Davicioni, Elai

Mayo Clinic

The Prostate | August 3, 2019 | Volume: 79 | Issue: 14 | Pages: 1589-1596

10.1002/pros.23882 | PMID 31376183 Get It

AbstractBackgroundMolecular studies have tried to address the unmet need for prognostic biomarkers in prostate cancer (PCa). Some gene expression tests improve upon clinical factors for prediction of outcomes, but additional tools for accurate prediction of tumor aggressiveness are needed.MethodsBased on a previously published panel of 23 gene transcripts that distinguished patients with metastatic progression, we constructed a prediction model using independent training and testing datasets. Using the validated messenger RNAs and Gleason score (GS), we performed model selection in the training set to define a final locked model to classify patients who developed metastatic‐lethal events from those who remained recurrence‐free. In an independent testing dataset, we compared our locked model to established clinical prognostic factors and utilized Kaplan‐Meier curves and receiver operating characteristic analyses to evaluate the model's performance.ResultsThirteen of 23 previously identified gene transcripts that stratified patients with aggressive PCa were validated in the training dataset. These biomarkers plus GS were used to develop a four‐gene (CST2, FBLN1, TNFRSF19, and ZNF704) transcript (4GT) score that was significantly higher in patients who progressed to metastatic‐lethal events compared to those without recurrence in the testing dataset (P = 5.7 × 10−11). The 4GT score provided higher prediction accuracy (area under the ROC curve [AUC] = 0.76; 95% confidence interval [CI] = 0.69‐0.83; partial area under the ROC curve [pAUC] = 0.008) than GS alone (AUC = 0.63; 95% CI = 0.56‐0.70; pAUC = 0.002), and it improved risk stratification in subgroups defined by a combination of clinicopathological features (ie, Cancer of the Prostate Risk Assessment‐Surgery).ConclusionOur validated 4GT score has prognostic value for metastatic‐lethal progression in men treated for localized PCa and warrants further evaluation for its clinical utility.
Flow Diversion of an Incompletely-Treated Fusiform Middle Cerebral Artery Aneurysm: 2-Dimensional Operative Video
Sorenson, Thomas J. , Klein, Jon P, Rangel-Castilla, Leonardo , Klein, Jon P. , Rangel-Castilla, Leonardo , Lanzino, Giuseppe

Mayo Clinic

Operative Neurosurgery | August 2, 2019 | Volume: 18 | Issue: 4 | Pages: E125-E126

10.1093/ons/opz186 | PMID 31375831 Get It

Abstract Fusiform aneurysms involving the M2 branches of the middle cerebral artery are often dissecting, identified by a characteristic diseased adjacent segment, and location not at a branch point. Herein, we present the case of a 38-yr-old man with a symptomatic, dissecting M2 aneurysm that was previously incompletely treated with stent-assisted coiling. In our experience, symptomatic fusiform aneurysms in this location tend to recur unless the involved segment is completely trapped or reconstructed with flow diversion. We successfully treated this patient with a vessel reconstruction using a Pipeline Flex Embolization Device (Medtronic). Deployment of a flow diverter inside a previously placed stent can pose potential challenges, as the original stent may constrain complete expansion of the flow diverter and prevent perfect apposition against the parent vessel wall. In this operative video, we demonstrate this technique and provide a brief discussion of the potential pitfalls.
Methods and resources to access mutation-dependent effects on cancer drug treatment
Yao, Hongcheng , Liang, Qian , Qian, Xinyi, Wang, Junwen , Sham, Pak C. , Li, Mulin Jun , Wang, Junwen

Mayo Clinic

Briefings in Bioinformatics | August 2, 2019 | Volume: 21 | Issue: 6 | Pages: 1886-1903

10.1093/bib/bbz109 | PMID 31750520 Get It

Abstract In clinical cancer treatment, genomic alterations would often affect the response of patients to anticancer drugs. Studies have shown that molecular features of tumors could be biomarkers predictive of sensitivity or resistance to anticancer agents, but the identification of actionable mutations are often constrained by the incomplete understanding of cancer genomes. Recent progresses of next-generation sequencing technology greatly facilitate the extensive molecular characterization of tumors and promote precision medicine in cancers. More and more clinical studies, cancer cell lines studies, CRISPR screening studies as well as patient-derived model studies were performed to identify potential actionable mutations predictive of drug response, which provide rich resources of molecularly and pharmacologically profiled cancer samples at different levels. Such abundance of data also enables the development of various computational models and algorithms to solve the problem of drug sensitivity prediction, biomarker identification and in silico drug prioritization by the integration of multiomics data. Here, we review the recent development of methods and resources that identifies mutation-dependent effects for cancer treatment in clinical studies, functional genomics studies and computational studies and discuss the remaining gaps and future directions in this area.